drugset
drugset / Trial / NCT05266729

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

NCT05266729 ↗

Phase 2 Completed 96 enrolled AMIpharm Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the dosing interval, optimal dose, evaluate safety, and efficacy of AYP-101 S.C injection for the reduction of Submental Fat (SMF).

Timeline

Start
2022-03-02
Primary completion
2022-12-28
Completion
2023-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Polyene Phosphatidylcholine Small molecule 25 mg/ml Subcutaneous
Subject Polyene Phosphatidylcholine Small molecule 50 mg/ml Subcutaneous

Indications

No indication recorded.